Lycia Therapeutics Inc. Company Profile
NASDAQ: LYCAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Lycia Therapeutics at a glance
Lycia Therapeutics Inc. (NASDAQ: LYCA) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in South San Francisco, CA. Lycia Therapeutics is led by Dr. Aetna Wun Trombley Ph.D. and employs about 31 people. The company's shares have traded publicly since 2026.
At a market capitalization of $1.72 billion, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001806540, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Lycia Therapeutics do?
Lycia Therapeutics, Inc., a biotechnology company, engages in the discovery and development of therapeutics designed to degrade disease-causing extracellular proteins for the treatment of autoimmune, inflammatory, and allergic diseases. The company develops the LYTAC platform, a modular technology designed to create therapeutics that selectively reduce the levels of pathogenic proteins. Its therapeutic candidate LCA-0061 degrades immunoglobulin E (IgE) for the treatment of allergic diseases, including food allergy. The company also develops LCA-0062, a follow-on program designed to degrade IgE for the treatment of allergic diseases. Additionally, it develops LCA-0321, a candidate designed to selectively degrade TSHR autoantibodies (thyrotropin receptor antibodies, or TRAbs), the pathogenic drivers of Graves' disease. Lycia Therapeutics, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
Business description based on the company's public filings.
Company information
- Legal name
- Lycia Therapeutics Inc.
- Ticker
- NASDAQ: LYCA
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Aetna Wun Trombley Ph.D.
- Employees
- 31
- Headquarters
- 400 East Jamie Court, South San Francisco, CA, United States
- Phone
- (650) 392-3357
- Website
- lyciatx.com
- IPO year
- 2026
- Market cap
- $1.72B
- SEC CIK
- 0001806540
Companies similar to Lycia Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MAZEMaze Therapeutics Inc. | 31.37 | -3.27% | $1.72B | vs LYCA |
| REPLReplimune Group Inc. | 19.07 | -0.83% | $1.81B | vs LYCA |
| COAGHemab Therapeutics Holdings Inc. | 39.29 | -1.43% | $1.84B | vs LYCA |
| BCRXBioCryst Pharmaceuticals Inc. | 7.22 | -1.37% | $1.86B | vs LYCA |
| VIRVir Biotechnology Inc. | 8.39 | -5.41% | $1.56B | vs LYCA |
| RXRXRecursion Pharmaceuticals Inc. Class A | 2.45 | -9.93% | $1.53B | vs LYCA |
| ALVOAlvotech | 4.12 | -3.96% | $1.47B | vs LYCA |
| WWBWindward Bio Group AG | 24.29 | +1.15% | $1.45B | vs LYCA |